← All Xeris Biopharma Holdings, INC filings

Xeris Biopharma Holdings, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
XERS
Xeris Biopharma Holdings, INC
10-K: Xeris Biopharma Achieves First Profit, Boosted by Recorlev
Xeris Biopharma Holdings, Inc. reported its first net income since inception in 2025, driven by strong growth in Recorlev sales and overall revenue increase.
NASDAQ
XERS
Xeris Biopharma Holdings, INC
10-K: Xeris Biopharma Reports 2024 Results, Highlights Growth in Key Products
Xeris Biopharma's 2024 10-K filing reveals a company focused on commercial growth and strategic partnerships despite ongoing losses and competitive pressures.
NASDAQ
XERS
Xeris Biopharma Holdings, INC
10-K: Xeris Biopharma Holdings, Inc. Files 10-K Report, Highlights Growth and Financial Strategies
Xeris Biopharma's 2023 10-K filing details the company's financial performance, strategic initiatives, and risk factors, emphasizing its focus on commercial growth and innovative product development.